November 25, 2024 • Books We Love returns with 350+ new titles handpicked by NPR staff and trusted critics. Find 12 years of recommendations all in one place — that's nearly 4,000 great reads.
Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).